公开(公告)号：US08338147B2

公开(公告)日：2012-12-25

申请号：US12779666

申请日：2010-05-13

Applicant: Niklas von Weymarn ,  Ulla Airaksinen

Inventor： Niklas von Weymarn ,  Ulla Airaksinen

IPC: C12P7/18

CPC classification number: C12P7/18

Abstract: High concentration of free cells of heterofermentative lactic acid bacteria (LAB) in a resting or slowly growing state are used to convert fructose into mannitol. Efficient volumetric mannitol productivities and mannitol yields from fructose are achieved in a process applying cell-recycle, continuous stirred tank reactor and/or circulation techniques with native LAB cells or with LAB cells with inactivated fructokinase gene(s). Mannitol is recovered in high yield and purity with the aid of evaporation and cooling crystallization.

Abstract translation: 使用高浓度的处于休眠或缓慢生长状态的异源发酵乳酸菌（LAB）的游离细胞将果糖转化为甘露醇。 在使用细胞循环，连续搅拌釜反应器和/或循环技术与天然LAB细胞或具有灭活的果糖激酶基因的LAB细胞的方法中，实现了来自果糖的高效体积甘露醇生产率和甘露醇产率。 在蒸发和冷却结晶的帮助下，以高产率和纯度回收甘露醇。

公开(公告)号：US09034602B2

公开(公告)日：2015-05-19

申请号：US13699434

申请日：2011-05-17

Applicant: Pertti Koski ,  Ulla Airaksinen ,  Katja Valimaki

Inventor： Pertti Koski ,  Ulla Airaksinen ,  Katja Valimaki

IPC: C12N9/86 ,  C12N9/78 ,  A61K38/50 ,  A61K45/06 ,  A61K31/43 ,  A61K31/545 ,  A61K38/00

CPC classification number: C12N9/86 ,  A61K9/0053 ,  A61K9/4891 ,  A61K31/43 ,  A61K31/545 ,  A61K38/00 ,  A61K38/50 ,  A61K45/06 ,  C12Y305/02006

Abstract: The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

Abstract translation: 本发明涉及药物和改性的β-内酰胺酶。 具体地，本发明涉及新型重组β-内酰胺酶和包含β-内酰胺酶的药物组合物。 此外，本发明涉及用于修饰β-内酰胺酶，产生β-内酰胺酶和治疗或预防β-内酰胺抗生素诱导的不良反应的方法。 此外，本发明涉及用作药物的β-内酰胺酶和β-内酰胺酶在制备用于治疗或预防β-内酰胺抗生素诱导的不良反应的药物中的用途。 此外，本发明涉及包含多核苷酸的多核苷酸和宿主细胞。

公开(公告)号：US06582944B1

公开(公告)日：2003-06-24

申请号：US09184965

申请日：1999-01-08

Applicant: Johan Hallborn ,  Merja Penttilä ,  Heikki Ojamo ,  Mats Walfridsson ,  Ulla Airaksinen ,  Sirkka Keränen ,  Bärbel Hahn-Hägerdal

Inventor： Johan Hallborn ,  Merja Penttilä ,  Heikki Ojamo ,  Mats Walfridsson ,  Ulla Airaksinen ,  Sirkka Keränen ,  Bärbel Hahn-Hägerdal

IPC: C12P706

CPC classification number: C12P19/02 ,  C12N9/0004 ,  C12N9/0006 ,  C12N15/52 ,  C12N15/81 ,  C12N15/905 ,  C12P7/06 ,  C12P7/18 ,  C12P7/40 ,  Y02E50/17 ,  Y02P20/582

Abstract: This invention relates to recombinant-DNA-technology. Specifically this invention relates to new recombinant yeast strains transformed with xylose reductase and/or xylitol dehydrogenase enzyme genes. A yeast strain transformed with the xylose reductase gene is capable of reducing xylose to xylitol and consequently of producing xylitol in vivo. If both of these genes are transformed into a yeast strain, the resultant strain is capable of producing ethanol on xylose containing medium during fermentation. Further, the said new yeast strains are capable of expressing the said two enzymes. Xylose reductase produced by these strains can be used in an enzymatic process for the production of xylitol in vitro.

Abstract translation: 本发明涉及重组DNA技术。 具体地说，本发明涉及用木糖还原酶和/或木糖醇脱氢酶基因转化的新的重组酵母菌株。 用木糖还原酶基因转化的酵母菌株能够将木糖还原成木糖醇，从而在体内产生木糖醇。 如果将这两个基因转化成酵母菌株，则所得菌株能够在发酵期间在含有木糖的培养基上产生乙醇。 此外，所述新酵母菌株能够表达所述两种酶。 由这些菌株产生的木糖还原酶可用于体外生产木糖醇的酶法。

公开(公告)号：US20130216622A1

公开(公告)日：2013-08-22

申请号：US13699434

申请日：2011-05-17

Applicant: Pertti Koski ,  Ulla Airaksinen ,  Katja Valimaki

Inventor： Pertti Koski ,  Ulla Airaksinen ,  Katja Valimaki

IPC: C12N9/86 ,  A61K45/06 ,  A61K38/50

CPC classification number: C12N9/86 ,  A61K9/0053 ,  A61K9/4891 ,  A61K31/43 ,  A61K31/545 ,  A61K38/00 ,  A61K38/50 ,  A61K45/06 ,  C12Y305/02006

Abstract: The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects.Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.

公开(公告)号：US20110091949A1

公开(公告)日：2011-04-21

申请号：US12779666

申请日：2010-05-13

Applicant: Niklas von Weymarn ,  Ulla Airaksinen

Inventor： Niklas von Weymarn ,  Ulla Airaksinen

IPC: C12P7/18

CPC classification number: C12P7/18

Abstract: High concentration of free cells of heterofermentative lactic acid bacteria (LAB) in a resting or slowly growing state are used to convert fructose into mannitol. Efficient volumetric mannitol productivities and mannitol yields from fructose are achieved in a process applying cell-recycle, continuous stirred tank reactor and/or circulation techniques with native LAB cells or with LAB cells with inactivated fructokinase gene(s). Mannitol is recovered in high yield and purity with the aid of evaporation and cooling crystallization.

Abstract translation: 使用高浓度的处于休眠或缓慢生长状态的异源发酵乳酸菌（LAB）的游离细胞将果糖转化为甘露醇。 在使用细胞循环，连续搅拌釜反应器和/或循环技术与天然LAB细胞或具有灭活的果糖激酶基因的LAB细胞的方法中，实现了来自果糖的高效体积甘露醇生产率和甘露醇产率。 在蒸发和冷却结晶的帮助下，以高产率和纯度回收甘露醇。

公开(公告)号：US5866382A

公开(公告)日：1999-02-02

申请号：US336198

申请日：1994-11-03

Applicant: Johan Hallborn ,  Merja Penttila ,  Heikki Ojamo ,  Mats Walfridsson ,  Ulla Airaksinen ,  Sirkka Keranen ,  Barbel Hahn-Hagerdal

Inventor： Johan Hallborn ,  Merja Penttila ,  Heikki Ojamo ,  Mats Walfridsson ,  Ulla Airaksinen ,  Sirkka Keranen ,  Barbel Hahn-Hagerdal

IPC: C12N1/15 ,  C12N1/19 ,  C12N9/02 ,  C12N9/04 ,  C12N15/52 ,  C12N15/81 ,  C12N15/90 ,  C12P7/06 ,  C12P7/18 ,  C12P7/40 ,  C12P19/02 ,  C12P7/02

CPC classification number: C12P19/02 ,  C12N15/52 ,  C12N15/81 ,  C12N15/905 ,  C12N9/0004 ,  C12N9/0006 ,  C12P7/06 ,  C12P7/18 ,  C12P7/40 ,  Y02E50/17 ,  Y02P20/582

Abstract: This invention relates to recombinant-DNA-technology. Specifically, this invention relates to new recombinant yeast strains transformed with xylose reductase and/or xylitol dehydrogenase enzyme genes. A yeast strain transformed with the xylose reductase gene is capable of reducing xylose to xylitol and consequently of producing xylitol in vivo. If both of these genes are transformed into a yeast strain, the resultant strain is capable of producing ethanol on xylose containing medium during fermentation. Further, the said new yeast strains are capable of expressing the said two enzymes. Xylose reductase produced by these strains can be used in an enzymatic process for the production of xylitol in vitro.

Abstract translation: 本发明涉及重组DNA技术。 具体地，本发明涉及用木糖还原酶和/或木糖醇脱氢酶基因转化的新的重组酵母菌株。 用木糖还原酶基因转化的酵母菌株能够将木糖还原成木糖醇，从而在体内产生木糖醇。 如果将这两个基因转化成酵母菌株，则所得菌株能够在发酵期间在含有木糖的培养基上产生乙醇。 此外，所述新酵母菌株能够表达所述两种酶。 由这些菌株产生的木糖还原酶可用于体外生产木糖醇的酶法。